Breakthrough Approach to Combat Cancer Drug Resistance
Overcoming drug resistance by reducing the amount and changing the distribution of P-gp. a Confocal images and fluorescence intensity of P-gp in NCI/RES-ADR multidrug-resistant cancer cells without any treatment (control) and after treated with LSC nanoparticles with laser irradiation (LSC + L, 1 W cm−2 for 1 min). The data show that the P-gp distributes not only on the cell plasma membrane but also in the cytoplasm after the LSC + L treatment, whereas it is dominantly located on the plasma membrane for the cells in the control group. Credit: doi:10.1038/s41467-018-02915-8
The ability for cancer cells to develop resistance to chemotherapy drugs - known as multi-drug resistance - remains a leading cause for tumor recurrence and cancer metastasis, but recent findings offer hope that oncologists could one day direct cancer cells to "turn off" their resistance capabilities.
New findings put forth by University of Maryland Fischell Department of Bioengineering Professor Xiaoming "Shawn" He and researchers from five other academic institutions point to a technique that uses specially designed nanoparticles and near infrared laser treatment to cause cancer cells to lose their multidrug resistance capabilities for days at a time. This creates a therapeutic window for chemotherapy to combat even the most drug-resistant cells left behind after surgery or earlier treatment. The group's findings were published in Nature Communications.
"By administering chemotherapy within this 'therapeutic window,' oncologists could apply a lower dose of chemotherapy drugs to patients, with the potential for an improved treatment outcome - all while minimizing drug toxicity to healthy organs," He said.
One of the primary reasons cancer cells develop resistance is the overexpression of what are known as efflux pumps - proteins that protect a cell by pumping out unwanted toxic substances before they can reach their intended target. In the same way that efflux pumps work hard to protect against toxins, they also expel virtually all clinically relevant chemotherapy drugs.
Fortunately, efflux pumps require a source of chemical energy to perform their function. As such, by cutting off the energy supply to the efflux pumps, oncologists could lower - or even eliminate - a cell's resistance to drugs, such as those administered for chemotherapy. Recognizing this, He and his research team developed a way to reduce the amount of chemical energy - adenosine triphosphate (ATP) - available to the efflux pumps in cancer cells.
The team - which also included researchers from Ohio State University, University of Virginia, University of Missouri School of Medicine, Shanghai University of Traditional Chinese Medicine, and Indiana University School of Medicine - targeted a specially designed nanoparticle to the mitochondrion, the cell's power generator wherein the cell converts oxygen and nutrients into ATP. Once the nanoparticles reach the cancer cells' mitochondria, the researchers apply near infrared laser treatment to trigger a chemical reaction that reduces the amount of ATP available to the pumps and, thus, cuts off their power supply. Such treatment both reduces the expression of the efflux pumps and decreases their distribution on the cell plasma membrane.
The research team's findings demonstrate that the drug-laden nanoparticles - in combination with near infrared laser treatment - can effectively inhibit the growth of multidrug-resistant tumors with no evident systemic toxicity.
While researchers have long worked with nanoparticles for drug delivery, the findings put forth by He and his team represent a crucial breakthrough in addressing multidrug resistance in cancer cells.
"For years, researchers have focused on delivering more chemotherapy drugs into cancer cells using nanoparticles, without targeting the root of drug resistance," He said. "This meant that the cancer cells maintained their ability to expel the chemotherapy drugs, which limited any enhancement of the cancer therapy. To address this challenge, our research group is using nanoparticles not only to deliver more chemotherapy drugs to the target site within cancer cells, but also to compromise the function of the efflux pumps and thereby significantly improve safety and efficacy of cancer therapy."
This article has been republished from materials provided by University of Maryland. Note: material may have been edited for length and content. For further information, please contact the cited source.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018